Trump's unprecedented levels of stock trading
A CBS News investigation shows President Trump has traded stocks at a level never before seen by an Oval Office occupant. CBS News investigative reporter Michael Kaplan has the details.
Watch CBS News
A CBS News investigation shows President Trump has traded stocks at a level never before seen by an Oval Office occupant. CBS News investigative reporter Michael Kaplan has the details.
CBS News medical correspondent Dr. Celine Gounder breaks down findings from a new study that takes a close look at popular GLP-1 weight loss drugs and their use during early pregnancy.
Some doctors and nurses are promoting and prescribing the weight-loss drug retatrutide, which has not yet been approved by the U.S. Food and Drug Administration, a CBS News investigation found. Adam Yamaguchi has more.
The weight loss drug retatrutide has been touted as "Ozempic on steroids." It's still in clinical trials and not approved by the FDA, but a CBS News investigation found that hasn't stopped doctors from offering it, and it could come with serious side effects. Adam Yamaguchi reports.
Approved 20 years ago as a diabetes treatment, GLP-1 drugs have been found to help patients reduce weight, changing the lives of more than 30 million people in the U.S. But there also have been troubling side effects reported.
Approved 20 years ago as a treatment for diabetes, GLP-1 drugs have been found also to help patients significantly reduce weight. More than 30 million people in the U.S. have had their lives changed by GLP-1 medications. But there have also been troubling side effects reported. Correspondent Tracy Smith talks with experts who say the drugs might prove useful in treating other diseases associated with obesity (including cancer); and with patients who have taken GLP-1 drugs and experienced widely varying reactions.
Researchers from Penn Medicine found women taking GLP-1 drugs are less likely to be diagnosed with breast cancer. Dr. Celine Gounder breaks down the study's findings and if the drugs caused the difference.
A new weight-loss drug, so new it is not on the market yet, is showing promising results in trials, doing much more than what current medications can. Dr. Jon LaPook breaks it down.
Outspoken body acceptance advocate Katie Sturino, who is the founder of Megababe Beauty, explains why it was a difficult decision for her to start taking weight loss drugs. She's joined by psychiatrist Dr. Sue Varma who breaks down what people should do before taking a GLP-1 and the impact of societal pressure.
The FDA approved a new GLP-1 drug from Eli Lilly. Dr. Jon LaPook breaks it down.